Bempedoic Acid for High Cholesterol in Children
(CLEAR Path 1 Trial)
Trial Summary
What is the purpose of this trial?
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
Will I have to stop taking my current medications?
Participants must continue taking their current stable lipid-modifying therapy (like statins) at the same dose throughout the trial.
What data supports the effectiveness of the drug Bempedoic acid for high cholesterol in children?
Bempedoic acid has been shown to effectively lower cholesterol levels in adults, particularly in those with familial hypercholesterolemia (a genetic condition causing high cholesterol) and those who cannot tolerate statins. It works by reducing cholesterol production in the liver, and studies have demonstrated its safety and efficacy in lowering LDL cholesterol (the 'bad' cholesterol) in these populations.12345
Is bempedoic acid safe for humans?
Bempedoic acid has been shown to be safe in several studies for lowering cholesterol, with a reduced risk of muscle-related side effects compared to some other treatments. It is approved for use in the USA and EU, and studies have not shown an increase in side effects when combined with other cholesterol-lowering drugs.12346
How is the drug bempedoic acid different from other treatments for high cholesterol?
Research Team
Michael Louie, MD
Principal Investigator
Esperion Therapeutics, Inc.
Jeffrey C Hanselman, MS
Principal Investigator
Esperion Therapeutics, Inc.
Eligibility Criteria
This trial is for children aged 6-17 with HeFH (a genetic cholesterol disorder) who have high LDL cholesterol levels despite taking other lipid-modifying medications. They must not have diabetes, extremely high triglycerides, or be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive bempedoic acid once daily with dose adjustments based on body weight for a total of 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bempedoic acid
Bempedoic acid is already approved in United States, European Union for the following indications:
- Hypercholesterolemia in combination with diet and the highest tolerated statin therapy in adults with heterozygous familial hypercholesterolemia, or with established atherosclerotic cardiovascular disease, who need additional lowering of LDL cholesterol
- Primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin; or alone or in combination with other lipid-lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated
Find a Clinic Near You
Who Is Running the Clinical Trial?
Esperion Therapeutics, Inc.
Lead Sponsor